SYCP2 and ovarian carcinoma: Among all the pathways targeted by drugs, the resistance to drugs targeting the DDR pathway showed the strongest positive correlation with the expression of SYCP2 in several cancer types including breast and ovarian cancers (Supplementary Fig. 1E).